IL6 and neoplasm: Thus IL6 stimulation has been linked with defective pericyte coverage and our findings show that both lower levels of pericyte coverage in the tumour vasculature and lower systemic IL6 levels are biomarkers for predicting enhanced survival following treatment with bevacizumab.